Peer-reviewed evidence
The foundational review by Aggarwal et al. (2007) catalogued curcumin's activity against over 30 different molecular targets, establishing it as one of the most pleiotropic natural compounds studied in modern pharmacology [1]. The paper documented curcumin's inhibition of NF-κB activation by several different inducers, including TNF, phorbol ester, and hydrogen peroxide, across multiple cell lines.
Hewlings and Kalman (2017) conducted a comprehensive review of clinical and preclinical data, confirming curcumin's anti-inflammatory and antioxidant effects while highlighting the dose-response relationship [2]. Their analysis noted that most positive clinical outcomes occurred at doses of 500–2,000 mg/day of curcumin extract (not whole turmeric), and that standardized extracts with verified curcuminoid content produced more consistent results than unstandardized preparations.
He et al. (2015) focused specifically on the NF-κB and MAPK signaling pathways, demonstrating that curcumin suppresses inflammatory responses in models of arthritis, cardiovascular disease, and metabolic syndrome [3]. Their work showed that curcumin's inhibition of IκB kinase (IKK) prevents the phosphorylation and degradation of IκBα, keeping NF-κB sequestered in the cytoplasm rather than translocating to the nucleus to activate inflammatory gene transcription.
Jurenka (2009) reviewed curcumin's anti-inflammatory properties across multiple clinical trials, finding significant reductions in C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) in patients with rheumatoid arthritis and post-surgical inflammation [4]. The review noted that curcumin's safety profile was favorable at doses up to 8 g/day in short-term studies, with gastrointestinal discomfort as the most commonly reported side effect at higher doses.
Taken together, the literature supports curcumin as a legitimate anti-inflammatory and antioxidant agent with activity across multiple molecular targets. The primary limitation across studies remains bioavailability — a challenge addressed in detail in the companion article on bioavailability.